Phase 3 LITESPARK-012 Misses End Points in Advanced RCC

Results from the phase 3 LITESPARK-012 trial (NCT04736706) demonstrate that intensifying an established first-line regimen did not improve outcomes in patients with advanced renal cell carcinoma (RCC), according to findings shared in a news release.

Two experimental strategies, each building on the combination of pembrolizumab (Keytruda) and lenvatinib (Lenvima), failed to significantly improve overall survival (OS) or progression-free survival (PFS) compared with the current standard of care.

For oncology nurses, these findings underscore the continued role of pembrolizumab plus lenvatinib as a frontline option and highlight the complexity of further improving outcomes through triplet or novel combination approaches.

No OS or PFS benefit observed with investigational combinations

LITESPARK-012 evaluated two investigational regimens in the first-line setting: belzutifan added to pembrolizumab plus lenvatinib; and lenvatinib combined with a co-formulation of pembrolizumab and the investigational anti–CTLA-4 antibody quavonlimab.

At interim analysis, neither regimen met the dual primary end points of OS and PFS. Specifically, the addition of belzutifan or quavonlimab did not significantly reduce the risk of disease progression or death compared with pembrolizumab plus lenvatinib alone.

From a nursing perspective, these findings reinforce that more intensive regimens do not necessarily translate into improved efficacy, despite increasing treatment complexity. Importantly, safety profiles for both investigational arms were consistent with prior data, with no new safety signals identified. This consistency remains clinically relevant for nursing teams involved in toxicity monitoring and patient education, particularly with multi-agent regimens that may increase cumulative adverse event burden.

Evolving treatment landscape in advanced RCC

Renal cell carcinoma represents approximately 80% of kidney cancers, with clear cell histology accounting for the majority of cases. A substantial proportion of patients present with advanced or metastatic disease requiring systemic therapy.

The treatment paradigm has shifted toward combination regimens incorporating immune checkpoint inhibitors and vascular endothelial growth factor (VEGF)–targeted therapies. Pembrolizumab plus lenvatinib remains a widely used first-line option, supported by robust efficacy data demonstrating improvements in survival outcomes.

Belzutifan, a hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, has shown activity in previously treated RCC and in von Hippel–Lindau–associated tumors. Its evaluation in the frontline setting was based on the hypothesis that targeting tumor hypoxia pathways could enhance responses when combined with immunotherapy and antiangiogenic agents.

Study design, patient population, and end points

LITESPARK-012 was a randomized, phase 3 trial designed to assess whether novel combinations could improve outcomes over standard therapy in treatment-naïve patients with advanced RCC.

Patients were randomized to receive one of the investigational combinations or pembrolizumab plus lenvatinib. The primary end points were OS and PFS, both standard measures in oncology trials evaluating survival benefit and disease control.

The interim analysis concluded that neither experimental arm achieved statistically significant improvements in these outcomes. Additional analyses are ongoing to further characterize efficacy and safety across subgroups.

Approximately 1,600 patients were enrolled, primarily with clear cell RCC, providing a large and clinically representative cohort. The inclusion of a broad patient population enhances the applicability of findings to routine oncology practice.

For oncology nurses, this reinforces that the study results are relevant to commonly encountered patient populations in both academic and community settings, including those initiating first-line systemic therapy.

Clinical implications for oncology nursing practice

Although LITESPARK-012 did not meet its primary end points, the findings provide important context for clinical decision-making and patient care. The absence of added benefit with more complex regimens highlights the importance of balancing efficacy with tolerability and quality of life.

Oncology nurses play a central role in:

• Educating patients on expected outcomes with standard-of-care regimens
• Monitoring and managing adverse events associated with immunotherapy and targeted therapy combinations
• Supporting adherence and symptom reporting in multi-agent treatment plans

These results also emphasize the ongoing need for clinical trial participation to identify more effective frontline strategies. Continued research is exploring alternative mechanisms and sequencing approaches to improve outcomes in advanced RCC.

Reference

1. Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC). Merck. April 21, 2026. Accessed April 21, 2026. https://www.businesswire.com/news/home/20260421205834/en/Merck-and-Eisai-Provide-Update-on-Phase-3-LITESPARK-012-Trial-Evaluating-First-Line-Combination-Treatments-for-Certain-Patients-With-Advanced-Renal-Cell-Carcinoma-RCC.